Results

1–6 of 6 results for farcimab

An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023
Expert Panel: AI
Mark S. Humayun, MD, PhD
Devinder S Chauhan, MD FRCOphth FRANZCO
Ursula M. Schmidt-Erfurth, MD
Jennifer I. Lim, MD, FARVO, FASRS
Royce WS Chen, MD
Annual Meeting Talks
2024
Faricimab Response is Associated With Intraocular Pressure Lowering in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Tamara L Lenis, MD, PhD
Annual Meeting Talks
2024
Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Aude Ambresin, MD, PD
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024
12-Month Real-World Clinical and Anatomic Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2024